CytoReason and Pfizer extend collaboration

By The Science Advisory Board staff writers

February 11, 2022 -- CytoReason has extended its collaboration agreement with Pfizer to investigate challenging biological questions that potentially inform the development of new therapies for the benefit of patients.

Since launching the collaboration in 2019, Pfizer has used CytoReason's models in Pfizer's research to enhance the understanding of the immune system in pursuit of developing innovative drugs. CytoReason's platform has provided Pfizer with multiple insights in a number of R&D programs across over 20 diseases, according to CytoReason.

No further financial details were disclosed.

CytoReason's multidisciplinary team of 65 leading biologists, bioinformaticians, and data engineers has developed a technology that enables pharma and biotech companies to speed drug R&D and bring novel therapies to the patients who most need them.

Pfizer collaborates with Acuitas, Beam Therapeutics
Pfizer and Acuitas Therapeutics have entered into a development and option agreement under which Pfizer may license on a nonexclusive basis Acuitas' liquid...
Pfizer to acquire Arena Pharmaceuticals
Pfizer will acquire all outstanding shares of Arena Pharmaceuticals for $100 per share in an all-cash transaction for a total equity value of approximately...
Memorial Sloan Kettering signs deal with Abintus Bio
Memorial Sloan Kettering Cancer Center has agreed to allow its next generation signaling technology 1XX to be used in Abintus Bio's in vivo CAR X products.
AI drug development startups raised $2.1B in 1st half of 2021
The market for artificial intelligence (AI) in drug development and discovery has been red-hot in recent years. The potential impact that AI can offer...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter